Evidence map›Paper›PMID 35588498›Full record

ReviewVeterinary medicine and science2022

Beneficial and toxicological aspects of zinc oxide nanoparticles in animals.

Heshu Sulaiman Rahman, Hemn Hassan Othman, Rasedee Abdullah, Hareth Yahya Ahmed Shujaa Edin, Nagi A Al-Haj

Abstract readReview
In one paragraph

Review in Veterinary medicine and science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Comparable Toxicity of Surface-Modified TiOAntioxidants (Basel, Switzerland) · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Heshu Sulaiman RahmanDepartment of Physiology, College of Medicine, University of Sulaimani, Sulaimaniyah, Republic of Iraq.ORCID 0000-0003-0356-0399
Hemn Hassan OthmanDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Sulaimani, Sulaimaniyah, Republic of Iraq.
Rasedee AbdullahDepartment of Veterinary Laboratory Diagnosis, Faculty of Veterinary Medicine, Universiti Putra Malaysia, Serdang, Malaysia.
Hareth Yahya Ahmed Shujaa EdinInstitute of Bioscience, Universiti Putra Malaysia, Serdang, Malaysia.
Nagi A Al-HajFaculty of Medicine and Health Sciences, Sana'a University, Sana'a, Yemen.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanotechnology is a far-reaching technology with tremendous applications in various aspects, including general medicine, veterinary medicine, agriculture, aquaculture, and food production. Nanomaterials have exceptional physicochemical characteristics, including increased intestinal absorption, biodistribution, bioavailability, and improved antimicrobial and catalytic properties. Although nanotechnology is gaining ground in animal management, husbandry, and production, its wide use is still hampered by occasional toxicity and side effects. Zinc oxide nanoparticles (ZnO-NPs) have long been utilized in animal production, aquaculture, and pet animal medicine. However, the use ZnO-NPs in animals has been associated with reports of toxicity and side effects. ZnO-NPs may have shown numerous beneficial effects in animals; its use must be regulated with care to avoid unwanted consequences. Thus, this review emphasizes the usage of ZnO-NPs in animal production and laboratory animals and the potential side effects associated with the use of nanoparticles as a feed supplement and therapeutic compound.

Indexed as

NanoparticlesZinc OxideAnimalsAnti-Bacterial AgentsBiological AvailabilityTissue DistributionAnti-Bacterial AgentsZinc Oxideadvantagenanomaterialstoxicityveterinary medicinezinc oxide nanoparticle

Identifiers

PMID35588498
PMCPMC9297768

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.